

AD _____

GRANT NUMBER DAMD17-96-1-6155

TITLE: Role of Estrogen Receptor Target Genes in Breast Cancer

PRINCIPAL INVESTIGATOR: Ming-Jer Tsai, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, TX 77030-3498

REPORT DATE: July 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970910 077

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1997	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 96 - 30 Jun 97)	
4. TITLE AND SUBTITLE Role of Estrogen Receptor Target Genes in Breast Cancer			5. FUNDING NUMBERS DAMD17-96-1-6155	
6. AUTHOR(S) Ming-Jer Tsai, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, TX 77030-3498			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) The aim of this project is to understand the mechanism of transition of breast cancer from hormone-dependent state to hormone-independent state. In order to pursue this question we have designed a regulatable regulator that can recognize all estrogen receptor target genes and put them under the regulation of exogenous compound RU486. In the presence of RU486, this regulator can bind to all estrogen targets and shut down their expression. We want to use this regulator to study the role of estrogen receptor target genes on breast cancer cell growth in hormone-dependent and hormone-independent states. In the last year, using a cellular culture system, we have successfully constructed this regulator and demonstrated that it can shut down an estrogen receptor reporter gene. With the success of this regulator, now we can answer what we set out to do in the next grant period. <div style="text-align: right;">THIS QUALITY INSPECTED 4</div>				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

MJT DK Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

MJT DK In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

~~AB~~ N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

MJT ~~YV~~ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

MJT ~~YV~~ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


 7/3/97
PI - Signature Date

Table of Contents

Front Cover Page	1
Standard From (SF) 298 - Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Body	6
Conclusions	8
References	8
Appendix	9
Attachments	10

Introduction

Breast cancer is the most frequent cancer in American women (1). Despite extensive studies undertaken to understand the etiology of breast cancer, no clear picture has emerged. It is thought that genetic, dietary, hormonal, environmental and lifestyle factors contribute to the incidence of this disease (1). In contrast to many other cancers, the incidence of breast cancer has steadily increased with a 24% increase between 1973 and 1987 (1). Thus, breast cancer remains a major problem to overcome in the improvement of women's health in America.

Previous attempts to identify genes responsible for breast cancer have identified several oncogenes, such as *wnt-1* (int-1), *wnt-3* and *int-2*, whose increased expression is frequently observed in MMTV-induced tumors(2). Furthermore, expression of these genes in mammary epithelial cells enables them to continue to grow even in a dense culture (3-5). These results provide strong evidence for their involvement in tumor development. The oncogenic potential of these genes has been demonstrated in transgenic animals. In addition, mutation of several tumor suppressor genes has also been shown to correlate with breast cancer (6,7).

Steroid hormones, estrogen and progesterone, and their receptors have also been demonstrated to be associated with breast cancer. Breast cell proliferation in response to estrogen and progesterone increases this proliferation potential. In addition, breast tumors rarely develop in ovariectomized woman (8). Furthermore, some women with breast cancer have higher estrogen levels than healthy control women (1) and antiestrogen treatment in breast cancer patients drastically reduces tumor reoccurrence (8,9). Finally, a strong correlation exists between reproductive history and the incidence of breast cancer (10).

It is well documented that initial breast cell growth and breast carcinoma is hormone-dependent. Antiestrogen treatment results in the arrest or remission of breast cancer growth (8,9). However, subsequently, most advanced breast cancers become resistant to estrogen-ablation therapy (11). It has been proposed that mutation of the estrogen receptor (ER) to a constitutively active regulator or to a receptor which can be activated by estrogen antagonist, tomaxifen, may contribute to the transition from estrogen-dependent to -independent tumor growth [for review see (11)]. However, half of all advanced breast cancers are receptor positive but resistant to antiestrogen therapy and some ER negative tumors behave as if they are ER positive in expression of ER target genes such as progesterone receptor. Furthermore, many of ER mutations identified in tumor cells are also found in healthy cells of breast cancer patients or healthy individuals. thus, it remains controversial whether ER mutations have primary role in the transition from estrogen-dependent to -independent state.

In this proposal, we design experiments to dissect the role of ER target genes in the growth of breast cancer and to understand how transition from estrogen-dependent to-independent cancer growth occurs. We expect that results obtained from these studies will help us to devise a way to control breast tumor growth.

In the last year since we obtained the support for DAMD we have successfully constructed several regulators that can shut down the expression of ER dependent target reporter in a test transfection system. These results are discussed in detail in the next section.

A. Experimental Methods

(i) Plasmid construction

KRAB domain and E2F1 DNA binding domain were amplified from pBXG1/Kid-1N and pCMV-E2F1 and ligated together by PCR. The resultant fragment was cut by XbaI and EcoRI and inserted into MCS sites of pBS-KSII(+) to constructed pKS-KE. The truncated PR-LBD(-19)-KRAB fusion fragment was amplified from pCEP4/GLK by PCR. The PCR product was cut by DraI and EcoRI, terminal end fill-in by klenow, then blunt-end ligated into EcoRV site of pKS-KE. The resultant plasmid pKS-KEPE contains functional KRAB domain at both N- and C-terminals of chimeric construct. E2F1 BNA binding domain was cut out using BamHI and EcoRI and replaced by PCR amplified ER DNA-binding domain to generate regulatable repressor of ER target genes pKS-KEDPK. The plasmid pKS-KEDPK was then subcloned into pCMX expression vector and checked in frame and by sequence analysis and by *in vitro* transcription/translation. The primers used for PCR amplification (5' primer; 3' primer) are as follows:

KRAB: AAGCTTCTAGACTGCAGCTCGAGGCCACCATGGCTCCTGAGCAAAG;
CCGCTTCACGGGATCCTCTCCTTGCTG.

E2F1-DBD: GAGGATCCCGTCAAGCGGAGGCTGGAC;
CCGGAATTCGGAGATCTGAAAGTTCTC.

ER-DBD: CGCGGATCCTATGGAATCTGCCAAGGAG;
CGGAATTCAGACCCCACTTCACCCCTG.

PR-LBD &

KRAB fusion: CGCGGATCCTTTAAAAAGTTCAATAAAGTCAGAG;
CCGGAATTCTCATCCTTGCTGCAACAGGGAG.

(ii) Transfection

Hela cells were routinely maintained in Dulbecco's Modified Medium (DMEM; Gibco, Gaithersburg, MD) supplemented with 10% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT). Cells were seeded 24 hours before transfection in 6-well tissue culture plates (2 x 10⁵ cells per well) in phenol red-free DMEM contained 10% charcoal/dextran treated FCS. DNA was introduced into cells using lipofectin (Gibco, Gaithersburg, MD) following the technique instruction. Cells were transfected for 6 hours and then washed with phosphate buffer to remove the lipofectin. Cells were incubated for an additional 24 hours in phenol red-free medium containing 10% charcoal/dextran treated FCS with or without hormones, as indicated in the text. Cell extracts were prepared by adding 30μl lysis buffer (Promega, Madison, WI) and assayed for luciferase activities (Monolight 2010 Luminometer, Analytical Luminescence Laboratory, MI). All determinations were performed in quadruple in at least two independent experiments.

B. Results and Discussion

The plasmid pCMX-KEDPK expressing chimeric repressor of ER was constructed which contained a KRAB repressor domain at both N- and C-terminals, an ER DNA-binding domain and a truncated progesterone receptor ligand-binding domain. The construct was confirmed by sequence analysis. An expected size of the

chimeric protein was produced by *in vitro* transcription/translation (data not shown). The capacity of repressor KEDPK to block the ER mediated transcription was tested by co-transfecting plasmids carrying KEDPK, human ER and 3(ERE) tataLuc into HeLa cells (Figure 1). The luciferase activity was measured 24 hours following treatment with 17 β -estradiol and Ru486. In the presence of Ru486 (10nM) the repressor KEDPK significantly inhibits the luciferase activity induced by ER. Fifty percent inhibition was observed when transfected equally amount of ER and repressor KEDPK. The inhibitory potency of KEDPK on ER transcription activity was shown in a dose-dependent manner (Figure 2). KEDPK did not interfere the transcription activity of ER in the absence of Ru486. The inhibitory activity of KEDPK was tightly regulated by Ru486, with maximal effect at concentration of 10 nM (Figure 3). Similar results were observed in breast cancer cell line MCF-7. The inhibitory activity of KEDPK was specific to the ER, since the repressor has shown no effect on other nuclear receptor systems tested so far in transient transfection (Figure 4).

Figure 1 INHIBITION OF ER ACTIVITY BY KEDPK




Figure 3 DOSE-DEPENDENT INHIBITION OF ER ACTIVITY




Figure 2 INHIBITION OF ER ACTIVITY BY KEDPK IN DOSE-DEPENDENT MANNER





Figure 4 EFFECT OF KEDPK ON GR ACTIVITY



It is concluded that the chimeric repressor we designed could potentially and specifically inhibit ER target gene expression in response to exogenous ligand. This provided a useful tool to study the role of ER target genes breast cancer progression, and can be used as innovative strategies for gene therapy of breast cancer. Recently, we have successfully established cell lines from E₂-dependent MCF7 and E₂-independent MCF7-derived LTSD cells. Currently, we are analyzing the effectiveness of our regulator in shutting down ER target genes, P52, Myc and progesterone receptor, in a Ru486 dependent manner. These cell lines will then be used to study the role of ER target genes on transition of breast cancer cells from E₂-dependent to E₂-independent state.

Conclusions

In the last year, we have made major progress toward our goals to understand the transition of breast cancer cells from E₂-dependent to E₂-independent state. We have successfully constructed a regulator that can shut down ER target genes in a Ru486-dependent manner. We have tested it in a transfection system and it was shown to work well and specifically. We also successfully established stable cell lines from E₂-dependent and -independent MCF7 cells. Its validity and effectiveness in controlling breast cancer cell growth will be tested in the coming year. We are optimistic that we will accomplish what we have proposed to do.

References

1. Henderson, B. E., Ross, R. K., and Pike, M. C. (1991) *Science* 254, 1131-1138.
2. Callahan, R.(1987) in *The Mammary Gland Development, Regulation and Function*. (Neville, M. C. and Daniel, C. Eds.), pp. 323-351, Plenum Publishing Inc. New York.
3. Brown, A. M. C., Wildin, R. S., Prendergast, T. J., and Varmus, H. E. (1986) *Cell* 46, 1001-1009.
4. Nusse, R. and Varmus, H. E. (1992) *Cell* 69, 1073-1087.
5. Rijssenijk, F., Van Deemter, L., Wagenaar, E., Sonnenberg, A., and Nusse, R. (1987) *EMBO J.* 6, 127-131.
6. Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E. (1995) *Genes and Dev.* 9, 882-895.
7. Boyd, M., Harris, F., McFarlane, R., Davidson, H. R., and Black, D. M. (1995) *Nature* 375, 541-542.
8. Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. (1992) *N. Engl. J. Med.* 327, 390-396.
9. Jodan, V. C. (1992) *J. Natl. Cancer Inst.* 84, 231-234.
10. Kelsy, J. L. and Gammon, M. D. (1991) *Cancer J. Clin.* 41, 146-165.
11. Horwitz, K. B.(1994) in *Receptor-Mediated Biological Processes:Implications for Evaluating Carcinogenesis*. pp. 29-45, Wiley-Liss,Inc.

Appendix

Abstract submitted to October meeting on Breast Cancer.

ROLE OF ESTROGEN RECEPTOR TARGET GENES IN BREAST CANCER

Dr. Zhi-Qing Ma, Dr. Sophia Y. Tsai and Dr. Ming-Jer Tsai

Department of Cell biology, Baylor College of Medicine
One Baylor Plaza, Houston, Texas 77030

Several lines of evidences indicate that breast cancer requires estrogen for initiation and maintenance until it progresses to a more aggressive stage. Two-third of estrogen receptor (ER) positive cancer patients initially response to anti-estrogen treatment and show tumor regression. Subsequently, most breast cancer cases cease to responsd to estrogen ablative therapy and progress into an aggressive hormone-independent state. It has been proposed that the ER plays an important role in both hormone-dependent and independent states. The specific aim of this project is to study the role of ER target genes in the promotion of breast cancer and the transit from an estrogen-dependent to an estrogen-independent state. The approaches we used is to construct a regulatable repressor of ER target genes by linking the DNA-binding domain of ER with Kruppel-Associated Box (KRAB) repressor domain and a mutated progesterone ligand-binding domain which only responds to exogenous ligand. The regulatable repressor constructed in this way should bypass the alteration of signal transduction at ER level commonly occurred in breast cancer, including ER mutation, ligand-independent activation of ER. This repressor binds to ER responsive element (ERE) directly to turn off all the ER target genes in response to an exogenous ligand RU486. The construct was confirmed by sequencing and an expected size of the chimeric protein was produced by in vitro transcription/translation. The capacity of repressor to block the ER mediated transcription was tested by co-transfecting hER and an ERE containing reporter into Hela cells. In the presence of RU486 (10 nM) the repressor significantly inhibits the reporter activity induced by ER. The inhibitory potency on ER transcription activity was shown in a dose-dependent manner. The inhibitory activity of chimeric repressor was tightly regulated by RU486, with maximal effect at concentration of 10 nM. Similar results were observed in breast cancer cell line MCF-7. The inhibitory activity was specific to the ER, since the repressor has no effect on other nuclear receptor system tested.

**Key words: Estrogen Receptor Target Gene, Regulatable Repressor,
Tamoxifen Resistance, Breast Cancer**

This work was supported by the U.S. Army Medical Research and Materiel Command under DAMD-17-96-1-6155

It is concluded that the chimeric repressor we designed could specifically inhibit ER target gene expression in response to exogenous ligand. This provided a useful tool to study the role of ER target genes in breast cancer progression, and can be used as innovative strategies for gene therapy of breast cancer.

ROLE OF ESTROGEN RECEPTOR TARGET GENES IN BREAST CANCER

Dr. Zhi-Qing Ma, Dr. Sophia Y. Tsai and Dr. Ming-Jer Tsai

Department of Cell biology, Baylor College of Medicine
One Baylor Plaza, Houston, Texas 77030

Expression of estrogen receptor (ER) plays an important role in breast tumorigenesis. Patients with ER positive tumor show the greatest benefits by treatment with anti-estrogen, tamoxifen. Nevertheless, many patients are insensitive to tamoxifen treatment, and eventually those patients who initially respond to tamoxifen become resistant. Many factors may contribute to these changes, including ER mutation and altered signal transduction that affect the activity of the receptor. The specific aim of this project is to further study the role of ER target genes in the promotion of breast cancer and design a vector to shut off its activity.

We have designed a chimeric regulator which can bind specifically to the estrogen response element and directly inhibit estrogen receptor target genes in the presence of exogenous ligand, RU486, regardless of the participation of endogenous ER or its mutants. Here, we demonstrated that the protein constructed in this way could indeed effectively block the expression of ER target genes *in vitro* in cancer cell line. Its potency was tightly regulated by RU486. The effect of repressor was specific to ER target genes, since it had no effect on other nuclear receptors tested so far. The availability of this regulatable repressor provides us a powerful tool to dissect the role of ER target genes in the growth of breast cancer. The success of the regulatable repressor in shutting-off ER target genes will have far reaching effect on current hormone therapy as well as on designation of future strategy for gene therapy of breast cancer.

